Tilray, a Canadian vertically integrated supplier of medical cannabis, announced terms for its IPO on Monday.
The Nanaimo, Canada-based company plans to raise $135 million by offering 9 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Tilray would command a basic market value of $1.4 billion.
Tilray was founded in 2014 and booked $23 million in sales for the 12 months ended March 31, 2018. It plans to list on the Nasdaq under the symbol TLRY. Cowen is the sole bookrunner on the deal. It is expected to price during the week of July 16.
The article Canadian cannabis supplier Tilray sets terms for $135 million US IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
